Streetbeat News

Analyst Ratings

JAMF

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on Jamf Holding (NASDAQ:JAMF) but lowers the price target from $24 to $22.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:54 pm

JKHY

RBC Capital analyst Daniel Perlin has maintained a 'Sector Perform' rating on Jack Henry & Associates (NASDAQ:JKHY) and lowered the price target from $181 to $161.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:53 pm

RBT

Rubicon Technologies reported lower than expected Q3 revenue results, leading to a drop in its share price. Additionally, Canaccord Genuity downgraded the stock from Buy to Hold and reduced its price target from $3 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:51 pm

BIIB

Biogen Inc (NASDAQ:BIIB) reported better-than-expected Q3 earnings with sales of $2.53 billion, beating the consensus of $2.39 billion. However, the company revised its FY23 revenues to decline in a low-single-digit percentage versus FY22. Following the earnings announcement, Wells Fargo and RBC Capital increased their price targets on Biogen, while Wedbush cut its price target.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:49 pm

ARM

Analysts from BMO Capital, KeyBanc Capital Markets, Mizuho Securities, and Goldman Sachs remain bullish on Arm Holdings Plc (NASDAQ:ARM) despite concerns over royalty rates. The analysts highlighted the company's strong Q2 results, robust licensing growth, and its position as a global leader in semiconductor IP licensing. However, they noted a lower outlook for mobile royalties due to smartphone weakness. The analysts have set price targets ranging from $60 to $65.

Portfolio Pulse from Anusuya Lahiri

November 09, 2023 | 6:49 pm

LLY

NVO

The FDA has approved Eli Lilly's Zepbound, the first and only obesity treatment. The drug is expected to be available in the U.S. by the end of the year at a price 20% lower than Novo Nordisk's semaglutide 2.4 mg injection for weight loss. BMO Capital predicts the obesity market could reach $70 billion in the U.S. and $100 billion worldwide by 2035. Lilly's dual branding of tirzepatide as Mounjaro for Type 2 Diabetes and Zepbound for weight management is seen as a strategic move for long-term competitiveness. Truist remains bullish on Zepbound/Mounjaro, predicting peak global sales of $44 billion.

Portfolio Pulse from Vandana Singh

November 09, 2023 | 6:44 pm

HUBS

RBC Capital analyst Rishi Jaluria has reiterated an Outperform rating on HubSpot (NYSE:HUBS) and maintained a price target of $625.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:43 pm

BIRD

Allbirds reported a YoY decrease in Q3 EPS results and worse-than-expected revenue results. The company also issued Q4 revenue guidance below estimates. Wedbush and Telsey Advisory Group lowered their price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:43 pm

FLT

RBC Capital analyst Daniel Perlin has maintained a 'Sector Perform' rating on Fleetcor Technologies (NYSE:FLT) but lowered the price target from $277 to $270.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:42 pm

RAMP

LiveRamp Holdings, Inc. (NYSE:RAMP) reported better-than-expected Q2 results and issued strong Q3 guidance. The company's Q2 earnings were 43 cents per share, beating market estimates of 24 cents per share. Q2 sales were $160 million, exceeding expectations of $152.26 million. LiveRamp anticipates Q3 revenue of $165 million, compared to estimates of $163.11 million. Following the earnings announcement, analysts from Morgan Stanley, Susquehanna, and Benchmark increased their price targets on LiveRamp.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:41 pm